

## MONOCYTE TO LYMPHOCYTE BLOOD RATIO IN TUBERCULOSIS AND HIV PATIENTS: COMPARATIVE ANALYSIS, PRELIMINARY DATA

Guadagnino G.,<sup>1</sup> Serra N.,<sup>2\*</sup> Colomba C.,<sup>1</sup> Giammanco A.,<sup>1</sup> Mililli D., Scarlata F., Ciaccio M.,<sup>3</sup> Di Carlo P.<sup>1</sup>

<sup>1</sup> *Department of Sciences for Health Promotion and Mother-Child Care "G. D'Alessandro", University of Palermo, Italy*

<sup>2</sup> *School of Medicine and Surgery, University Federico II of Naples, Italy*

<sup>3</sup> *Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, Italy*

[\\*nicola.serra@unina.it](mailto:nicola.serra@unina.it)

### Abstract

Recent data confirmed the hypothesis suggested by historical studies that the ratio of peripheral blood monocytes to lymphocytes (M/L) is associated with the risk of tuberculosis (TB) disease. We retrospectively analyzed the electronic health records of tuberculosis and HIV-positive patients who had followed day-care programs at the AIDS Center of the University of Palermo, Italy.

261 patients were recruited and divided into 6 groups as follows: healthy control group (HCG: 47 pts), latent HIV negative infected TB group (LIG, 43 pts), active HIV negative tuberculosis (TAG: 61 pts), treated tuberculosis HIV negative (TTG: 44 pts), HIV drug-naive patients tested TST and QFT-IT-negative with negative chest x-Ray (HIVnG: 44 pts), and HIV-tuberculosis coinfection (HIVTB-G: 22 pts). For each group, absolute lymphocyte (L), monocyte (M) and M/L ratio by peripheral blood was calculated.

The mean value of monocytes in the TAG group was significant, the highest ( $0.70 \pm 0.37 \times 10^3/\mu\text{l}$ ) in comparison to HGC ( $0.70 > 0.44$ , p-value  $< 0.05$ ), HIVnG ( $0.70 > 0.40$ , p-value  $< 0.05$ ) and HIVTB-G ( $0.70 > 0.45$ , p-value  $< 0.05$ ). Monocyte to lymphocyte blood RATIO showed a significant difference between groups (p-value  $< 0.001$ ). In particular, the mean score of M/L ratio was higher in the TAG group compared to the HGC ( $0.49 > 0.27$ , p-value  $< 0.05$ ), LIG ( $0.49 > 0.29$ , p-value  $< 0.05$ ), TTG ( $0.49 > 0.32$ ) and HIVTB-G groups ( $0.49 > 0.27$ , p-value  $< 0.05$ ).

Our data confirm a significant difference in monocyte to lymphocyte blood ratio in tuberculosis disease. These data may be useful for monitoring and revising implementation plans for the different phases of tuberculosis disease (latent Mycobacterium tuberculosis (MTB) infection versus TB active disease).

Regarding HIV samples, the small sample size is somewhat offset by the need, fully satisfied in our sample, to enlist specific patients such as co-infected HIV/TBC who voluntarily submit to clinical trials in our geographical area.

**Keywords:** tuberculosis, monocyte to lymphocyte blood RATIO, HIV infection, co-infected HIV/TBC

## Introduction

The proportion of reported TB case notifications increased from 22% in 2008 to 63% in 2013 [1,2]. Over the last decade, the number of tuberculosis cases (TBCs) in foreign-born persons has more than doubled, and the percentage of total cases is approximately 50%. This is probably because of an ongoing influx of refugees from other countries, which can contribute to the diffusion in Italy of a non-autochthonous microorganism [3-5].

In the same period, the distribution of cases reported to the Ministry of Health by age class and "non-Italian citizens" shows that the highest number of cases occurs in the intermediate age classes, with a peak in the 25-34 group which, moreover, is the most represented among non-Italian citizens present in our country. Resistance among different species of microorganism to antimicrobial drugs has developed into a public health concern [6-8, 35-40,43].

Among these microorganisms, we find TB. Multidrug-resistant (MDR) TB has increased from 2008 to 2013, with 77.4% of strains isolated from migrants from 41 countries [8-10,50].

Finally, TB/HIV co-infection is a substantial problem in the EU/EEA. The occurrence of TB in HIV-positive cases and the low TB treatment success rate indicate that TB control efforts need to address the migrant population [11,12].

Recent studies focus on the prognostic value of lymphocytes, monocytes and calculated ratios in cancer and infected patients [12-15]. There is increasingly compelling evidence that natural killer (NK) cells play a crucial role in host defense against viral infection [44-46]. Monocyte to lymphocyte ratio might also identify children who are highly protected and those who are refractory to protection with some vaccination [41,42].

In view of recently published data on flow cytometry and phenotyping analysis regarding patients enrolled in our geographical area [12], we started the investigation to analyze blood cell count of lymphocytes, monocytes and monocyte/lymphocyte ratio in Italian and migrant HIV-infected and uninfected patients.

## Materials and Methods

The study participants were 261 Caucasian HIV negative and HIV-infected patients, consecutively enrolled between January 2016 and January 2017, who were being followed-up prospectively at the Department of Infectious Diseases, University Hospital of Palermo, Italy. Demographic and HIV disease characteristics were recorded and assessed as previously reported [16,17].

### *Full Blood Counts*

Leucocyte differential counts were performed at the "P. Giaccone" University Hospital, Pathology Laboratory, University of Palermo, Italy, an accredited clinical laboratory, using standard procedures on a Sysmex automated haematology analyser.

ML ratio was calculated as the quotient of absolute monocyte and lymphocyte counts.

We have defined as affected by active tuberculosis all patients with Mycobacterium tuberculosis complex (MTBC) isolated from biological samples, as previously reported [18-21].

Patients with microbiological diagnosis underwent tuberculosis treatment, according to guidelines [22].

We identified the following groups of patients:

1. Healthy control group (HCG): 47 HIV negative individuals who tested TST and QFT-IT-negative.
2. Latent HIV negative infected TB group (LIG): 43 HIV negative patients who reported household or equivalent close contact with smear-positive pulmonary TB patients in the previous 3 months, QFT-IT-positive, with negative chest x-ray results for active pulmonary lesions and no prior preventive therapy administered.
3. Active HIV negative tuberculosis (TAG): 61 patients with a microbiological diagnosis positive for Mycobacterium tuberculosis complex (53 with pulmonary tuberculosis and 7 with extrapulmonary tuberculosis).

4. Treated tuberculosis HIV negative (TTG): 44 cured TB patients who showed a previous microbiological diagnosis.
5. HIV drug-naive patients (HIVnG): 44 patients (mean of CD4 + = 300,59 mm<sup>3</sup>), tested TST and QFT-IT-negative with negative chest x-ray.
6. HIV-tuberculosis co-infection (HIVTB-G): 22 patients with TB diagnosis after two months of specific anti TB therapy (mean of CD4 = 70 ± 43,5 mm<sup>3</sup>).

Patient medical records were collected and entered into a hospital medical record database. Informed consent, including consent to the publication of patient details, was signed by all individuals before they accessed the day health care services, in accordance with the Declaration of Helsinki.

#### Statistical analysis

Statistical analysis was performed by Matlab statistical toolbox version 2008 (MathWorks, Natick, MA, USA) for Windows at 32 bit.

Data are presented as number and percentage for categorical variables and continuous data were expressed as mean ± standard deviation (SD), unless otherwise specified.

The multiple comparison chi-square test was used to define significant differences among percentages: if chi-square test was positive (p-value less than 0.05) then residual analysis with the Z-test to locate the highest or lowest significant presence was performed.

Multi-comparison tests on continuous data were performed with one-way ANOVA test to evaluate significant differences among means. If the ANOVA test was positive, Scheffé's method was performed for pairwise comparison. Finally only a p-value < 0.05 was considered as significant.

#### Results

In Table 1, we report the characteristics and multivariate analysis of the enrolled population by patient group: gender, age, country of origin (Italian/Migrant), lymphocyte and monocyte absolute blood count and monocyte to lymphocyte blood ratio.

We found a significant difference among groups for gender (M) (p-value < 0.0001): in particular, the HCG group had fewer males than any other (40.43%, p-value < 0.05).

As for age, no significant difference was found among groups (p-value = 0.207).

Regarding country of origin, there were significant differences between the groups (p-value < 0.0001): in particular, there were more Italian patients in the HCG group (100%, p-value < 0.05) and fewer in the TAG (22.95%, p-value < 0.05) and TTG groups (22.73%, p-value < 0.05).

As far as lymphocytes are concerned, there was a significant difference among groups (p-value < 0.001): in particular, mean value of lymphocytes was significantly greater in the LIG group than in TAG (2.22 > 1.70) (1x10<sup>3</sup>/μl) and HIVnG (2.22 > 1.45) (1x10<sup>3</sup>/μl).

As for monocytes, there was a significant difference between the groups (p-value < 0.001): in particular, the mean value of monocytes was significantly higher in the TAG group than in the HCG group (0.70 > 0.44) (1x10<sup>3</sup>/μl), HIVnG (0.70 > 0.40) (1x10<sup>3</sup>/μl) and HIVTB-G (0.70 > 0.45) (1x10<sup>3</sup>/μl).

Finally, monocyte to lymphocyte blood RATIO (M/L) showed a significant difference between groups (p-value < 0.001): in particular, the mean score of M/L ratio was higher in TAG than in the HCG (0.49 > 0.27), LIG (0.49 > 0.29), TTG (0.49 > 0.32) and HIVTB-G groups (0.49 > 0.27). In Figures 1 and 2 we show the mean value of lymphocytes, monocytes and monocytes/lymphocytes for each group.

#### Discussion

Tuberculosis is a leading cause of death worldwide despite the availability of effective chemotherapy for over 60 years. Although *Mycobacterium bovis* bacillus Calmette-Guérin (BCG) vaccination protects against tuberculosis complications, such as tuberculosis of the central nervous system [23,24], its efficacy is suboptimal and under debate in cancer patients and in

pregnant women [25,47]. Particularly, recent studies show a connection between preexisting tuberculosis and lung cancer [27,28]. In addition, a correlation between breast carcinoma and previous repeated fluoroscopies in the treatment of patients with tuberculosis has been considered [32]. Therefore in these cases more efficient new treatments and diagnostic procedures should be considered, especially for young people or patients with lung cancer [29-31,33,34].

In this study, we found that lymphocyte absolute count was lower in patients with active tuberculosis than in other uninfected HIV patients, and monocyte absolute count was higher in patients with active tuberculosis than in other uninfected HIV patients.

Regarding the statistical analysis, uninfected active tuberculosis patients had a significantly lower lymphocyte absolute count compared to latent infected patients; regarding monocytes, uninfected active tuberculosis patients had a significantly higher absolute count than the healthy subjects. These findings are in accordance with data we published previously [13,16].

HIV+ patients are at increased risk of contracting tuberculosis disease despite ARTs and number of CD4+ cells [48]. Disseminated infection by rapidly growing mycobacteria like *M. abscessus* subsp. *bolletii* in patients affected by idiopathic CD4+ T lymphocytopenia have been described [49]. HIV infection is characterized by a reduction in total white cell count (WCC), neutropenia and a particular reduction in CD4+ T cells but an increase in CD8+ T cells. In our study we found the lowest absolute lymphocyte cell count in ART naïve patients. We presume that this data is related to the underlying HIV infection.

Regarding monocyte absolute cell count, we did not find any significant difference between HIV negative and HIV positive patients, except for subjects with active tuberculosis.

Naranbhai et al. showed that in the HIV population the ratio of monocytes and lymphocytes (ML ratio) in peripheral blood is associated with tuberculosis. Our median monocyte count was 0.4, like the 50<sup>th</sup> percentile reported by Naranbhai [16] in HIV patients who

developed tuberculosis during follow-up. Similar data regarding absolute monocyte count were reported by Jun Wang for the Brazilian tuberculosis population [26].

In conclusion, our preliminary results confirm the evidence demonstrated in the in vivo and vitro study on immunocompetent patients with tuberculosis [13-16,26].

On the other hand, our study raises doubts about the role of M/L ratio in subjects in the HIV population, in naïve patients especially. To better outline its role as a tuberculosis biomarker for this group of patients, a larger number of enrolled subjects is needed.

The authors encourage future research to evaluate the "gray phase" of inflammatory response against *Mycobacterium tuberculosis*. In fact, the latent and reactivation phase remains a difficult step in patient management, especially HIV positive and cancer patients.

## References

1. European Centre for Disease Prevention and Control/ World Health Organization Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe, 2015. ECDC/WHO; 2015. DOI 10.2900/666960
2. Hollo V, Kotila SM, Ködmön C, Zucs P, van der Werf MJ. The effect of migration within the European Union/European Economic Area on the distribution of tuberculosis, 2007 to 2013. *Euro Surveill.* 2016;21(12). doi: 10.2807/1560-7917.ES.2016.21.12.30171.
3. Cervo A, Mancini F, di Bernardo F, Giammanco A, Vitale G, Dones P, Fasciana T, Quartaro P, Mazzola G, Rezza G. Louse-borne relapsing fever in young migrants, Sicily, Italy, July–September 2015. *Emerg Infect Dis*;22(1). 2016.
4. Colomba C, Scarlata F, Di Carlo P, Giammanco A, Fasciana T, Trizzino M,



- Cascio A. Fourth case of louse-borne relapsing fever in Young Migrant, Sicily, Italy, December 2015. Mini Review Article, Public Health (2016).
5. Gabutti G, Bergamini M, Bonanni P, Guido M, Fenoglio D, Giammanco A, Sindoni L, Zotti C, Boddi V, Bamfi F, Severini R, Bechini A, Boccalini S, Crovari P. Collaborative Group for the Study of Pertussis. Assessment of humoral and cell-mediated immunity against *Bordetella pertussis* in adolescent, adult, and senior subjects in Italy. *Epidemiol Infect.* 2008 Nov;136(11):1576-84. doi: 10.1017/S0950268807000192. Epub 2008 Jan 16.
  6. Gabutti G, Bergamini M, Bonanni P, Guido M, Fenoglio D, Giammanco A, Sindoni L, Zotti C, Boddi V, Bamfi F, Severini R, Bechini A, Boccalini S, Crovari P. Assessment of humoral and cell-mediated immunity against *Bordetella pertussis* in adolescent, adult, and senior subjects in Italy. *Epidemiol Infect.* 2008 Nov;136(11):1576-84.
  7. Fasciana T, Calà C, Bonura C, Di Carlo P, Matranga D, Scarpulla G, Manganaro M, Camilleri S, Giammanco A. Resistance to clarithromycin and genotypes in *Helicobacter pylori* strains isolated in Sicily. *J Med Microbiol.* 2015 Nov;64(11):1408-14.
  8. Mammina C, Calà C, Bonura C, Di Carlo P, Aleo A, Fasciana T, Giammanco A. EPI-MRSA Working Group. Polyclonal non multiresistant methicillin resistant *Staphylococcus aureus* isolates from clinical cases of infection occurring in Palermo, Italy, during a one-year surveillance period. *Ann Clin Microbiol Antimicrob.* 2012 Jun 19;11:17.
  9. Hojabri Z, Pajand O, Bonura C, Aleo A, Giammanco A, Mammina C. Molecular epidemiology of *Acinetobacter baumannii* in Iran: endemic and epidemic spread of multiresistant isolates. *J Antimicrob Chemother.* 2014 Sep;69(9):2383-7. doi: 10.1093/jac/dku045. Epub 2014 Feb.
  10. Del Giudice A, Mustazzolu A, Iacobino A, Perna R, Smeraglia R, Marino R, Fattorini L, Santoro G. Drug-resistant tuberculosis in Naples, 2008-2013. *Ann Ist Super Sanita.* 2016 Oct-Dec;52(4):603-607.
  11. Prestileo T, Spicola D, Di Lorenzo F, Dalle Nogare ER, Sanfilippo A, Ficalora A, Corrao S. Infectious diseases among foreign prisoners: results of a hospital-based management model in Palermo. *Infez Med.* 2017 Mar 1;25(1):57-63.
  12. van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. *AIDS.* 2016 Nov 28;30(18):2845-2853.
  13. La Manna MP, Orlando V, Dieli F, Di Carlo P, Cascio A, Cuzzi G, Palmieri F, Goletti D, Caccamo N. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. *PloS one.* 2017;12(2): e0171358.
  14. Naranbhai V, Fletcher HA, Tanner R, O'Shea MK, McShane H, Fairfax BP, ... & Hill AV. Distinct transcriptional and antimycobacterial profiles of peripheral blood monocytes dependent on the ratio of monocytes to lymphocytes. *EBioMedicine.* 2015;2(11): 1619-1626.
  15. He W, Wei M, Yang X, Chen B, Wu Q, Zheng E, Deng X, Wang Z. Do inflammatory markers predict prognosis in patients with synchronous colorectal cancer? *Medicine (Baltimore).* 2017 Apr;96(17):e6607.
  16. Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.
  17. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane H, Fletcher H. Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults

- Initiating Antiretroviral Therapy. *J Infect Dis.* 2014 Feb 15;209(4):500-9.
18. Di Carlo P, Guadagnino G, Immordino P, Mazzola G, Colletti P, Alongi I, Casuccio A. Behavioral and clinical characteristics of people receiving medical care for HIV infection in an outpatient facility in Sicily, Italy. Patient preference and adherence. 2016;10:919.
  19. Li Vecchi V, Soresi M, Giannitrapani L, Mazzola G, La Sala S, Tramuto F, Caruso G, Colomba C, Mansueto P, Madonia S, Montalto G, Di Carlo P. Dairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects. *BMC Infect Dis.* 2012 Aug 15;12:192.
  20. Bonura C, Gomgnimbou MK, Refrégier G, Aleo A, Fasciana T, Giammanco A, ... & Mammina C. Molecular epidemiology of tuberculosis in Sicily, Italy: what has changed after a decade? *BMC Infectious Diseases.* 2014;14(1): 602.
  21. Bonura C, Di Carlo P, Spicola D, Cal C, Mammina C, Fasciana T, Giammanco A. Rapidly growing mycobacteria in TB/HIV co-infection: a report of two cases focusing on difficulties in diagnosis and management. *New Microbiol.* 2012 Apr;35(2):239-43. Epub 2012 Mar 31.
  22. Saporito L, Florena AM, Colomba C, Pampinella D, Di Carlo P. Prurigo nodularis due to *Mycobacterium tuberculosis*. *J Med Microbiol.* 2009 Dec;58(Pt 12):1649-51.
  23. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, ... & O'Brien RJ. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. *Clinical Infectious Diseases.* 2017;64(2): e1-e33.
  24. Titone L, Di Carlo P, Romano A, Maggio MC, Salsa L, Abbagnato L, Mazzola A. Tuberculosis of the central nervous system in children: 32 years survey. *Minerva Pediatr.* 2004 Dec;56(6):611-7.
  25. Di Carlo P, Casuccio A, Romano A, Spicola D, Titone L, Caccamo N, Dieli F, Mammina C, Pace E, Gjomarkaj M, Melis M, Tolomeo M. Lymphocyte apoptosis in children with central nervous system tuberculosis: a case control study. *BMC Pediatr.* 2011 Nov 23;11:108.
  26. Colomba C, Di Carlo P, Guadagnino G, Siracusa L, Trizzino M, Gioè C, Cascio A. A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculosis infection. *Infect Agent Cancer.* 2016 Jun 2;11:25.
  27. Wang J, Yin Y, Wang X, Pei H, Kuai S, Gu L, Xing H, Zhang Y, Huang Q, Guan B. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. *Braz J Infect Dis.* 2015 Mar-Apr;19(2):125-31.
  28. Wu MF, Jian ZH, Huang JY, Jan CF, Nfor ON, Jhang KM, ... & Wu MC. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD. *BMC cancer.* 2016;16(1):778.
  29. Hong S, Mok Y, Jeon C, Jee SH, Samet JM. Tuberculosis, smoking and risk for lung cancer incidence and mortality. *International Journal of Cancer.* 2016;139(11): 2447-2455.
  30. Fiorelli A, D'Andrilli A, Vanni C, Cascone R, Anile M, Diso D et al. Iterative Surgical Treatment for Repeated Recurrences After Complete Resection of Thymic Tumors. *The Annals of Thoracic Surgery.* 2016 Apr;9(4):541-8.
  31. Fiorelli A, Santoriello C, Di Natale D, Cascone R, Musella V, Mastromarino R, ... & Santini M. In the era of ultrasound technology, could conventional trans-bronchial needle aspiration still play a role in lung cancer mediastinal staging? *Journal of Thoracic Disease.* 2017;9 (Suppl 5): S386.

32. Macchi M, Belfiore MP, Floridi C, Serra N, Belfiore G, Carmignani L et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. *Medical Oncology*. 2017;34(5): 96.
33. MacKenzie I. Breast cancer following multiple fluoroscopies. *British Journal of Cancer*. 1965;19(1):1.
34. Grassi R, Iannaccone T, Romano A, Serra N. Level and conditioning of knowledge in benign breast disease in very young patients. *Pharmacology Online Journal, Special Issue 2016*;1: 20-26.
35. Fiorelli A, Rauchi A, Cascone R, Reginelli A, Di Natale D, Santoriello C, Capuozzo A, Grassi R, Serra N, Polverino M, Santini M. Three-dimensional virtual bronchoscopy using a tablet computer to guide real-time transbronchial needle aspiration, *Interactive CardioVascular and Thoracic Surgery*. 2016:1-9.
36. Barberi G, De Cola MC, Dell'Utri P, Melardi S, Alagna B, Bramanti P, Cascio A. Antimicrobial consumption and antimicrobial resistance: a snapshot of an Italian neuromuscular rehabilitation center. *The New Microbiologica*. 2017;40(2): 119-129
37. Cascio A, Mezzatesta ML, Odierna A, Di Bernardo F, Barberi G, Iaria C, ... & Giordano S. Extended-spectrum beta-lactamase-producing and carbapenemase-producing *Enterobacter cloacae* ventriculitis successfully treated with intraventricular colistin. *International Journal of Infectious Diseases*. 2014; 20: 66-67.
38. Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, ... & David A. Post-neurosurgical multidrug-resistant *Acinetobacter baumannii* meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. *International Journal of Infectious Diseases*. 2010;14(7): e572-e579.
39. Iaria C, Stassi G, Costa GB, Biondo C, Gerace E, Noto A, ... & Cascio A. Outbreak of multi-resistant *Corynebacterium striatum* infection in an Italian general intensive care unit. *Journal of Hospital Infection*. 2007;67(1):102-104.
40. Cascio A, Stassi G, Costa GB, Crisafulli G, Rulli I, Ruggeri C, Iaria C. *Chryseobacterium indologenes* bacteraemia in a diabetic child. *Journal of Medical Microbiology*. 2005;54(7):677-680.
41. Iaria C, Stassi G, Costa GB, Di Leo R, Toscano A, Cascio A. Enterococcal meningitis caused by *Enterococcus casseliflavus*. First case report. *BMC Infectious Diseases*. 2005;5(1):3.
42. Warimwe GM, Fletcher HA, Olotu A, Agnandji ST, Hill AV, Marsh K, Bejon P. Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS, S malaria vaccine: analysis of pooled phase II clinical trial data. *BMC Medicine*. 2013;11(1):184.
43. Podda A, De Luca EC, Titone L, Casadei AM, Cascio A, Peppoloni S, ... & Rappuoli R. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12-to 24-and 2-to 4-month-old children. *The Journal of Pediatrics*. 1992;120(5):680-685.
44. Antinori S, Calattini S, Piolini R, Longhi E, Bestetti G, Cascio A. ... & Corbellino M. Is real-time polymerase chain reaction (PCR) more useful than a conventional PCR for the clinical management of leishmaniasis? *The American Journal of Tropical Medicine and Hygiene*. 2009;81(1): 46-51.
45. Di Bona D, Aiello A, Colomba C, Bilancia M, Accardi G, Rubino R, Giannitrapani L, Tuttolomondo A, Cascio A, Caiaffa MF, Rizzo S, Di Lorenzo G, Candore G, Duro G, Macchia L, Montalto




- G, Caruso C. KIRIIND (KIR Infectious and Inflammatory Diseases) Collaborative Group. KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection. *J Viral Hepat.* 2017; 24(9):768-775.
- Di Bona D, Scafidi V, Plaia A, Colomba C, Nuzzo D, Occhino C, Tuttolomondo A, Giammanco G, De Grazia S, Montalto G, Duro G, Cippitelli M, Caruso C. HLA and killer cell immunoglobulin-like receptors influence the natural course of CMV infection. *J Infect Dis.* 2014 Oct 1;210(7):1083-9.
46. Colomba C, Lalicata F, Siracusa L, Saporito L, Di Bona D, Giammanco G, De Grazia S, Titone L. Cytomegalovirus infection in immunocompetent patients. Clinical and immunological considerations. *Infez Med.* 2012 Mar;20(1):12-5.
47. Colomba C, Adamoli L, Trizzino M, Siracusa L, Bonura S, Tolomeo M, Cajozzo M, Giammanco GM. A case of visceral leishmaniasis and pulmonary tuberculosis in a post-partum woman. *Int J Infect Dis.* 2015 Apr;33:5-6. Epub 2014 Dec 15.
48. Colomba C, Siracusa L, Madonia S, Bonura S, Rubino R. Irreversible acute renal failure and cholestatic hepatitis following therapy with indomethacin in an HIV-naive patient with pericarditis: a case report. *Infez Med.* 2014 Sep;22(3):247-9.
49. Colomba C, Rubino R, Di Carlo P, Mammina C, Bonura C, Siracusa L, Titone L, Saporito L. Probable disseminated *Mycobacterium abscessus* subspecies *bolletii* infection in a patient with idiopathic CD4+ T lymphocytopenia: a case report. *J Med Case Rep.* 2012 Sep 4;6:277.
50. Sotgiu G, Dara M, Centis R, Matteelli A, Solovic I, Gratziau C, Rendon A, Battista Migliori G. Breaking the barriers: Migrants and tuberculosis. *Presse Med.* 2017 Mar;46(2 Pt 2):e5-e11.


**Table 1.** Characteristics for every group with multivariate analysis

Variable	HCG	LIG	TAG	TTG	HIVnG	HIVTB-G	Multivariate analysis: p-value
Patients	47	43	61	44	44	22	
Gender (M)	40.43%	76.74%	81.97%	81.82%	84.09%	77.27%	<0.0001 (C) * HCG *** (Z)
Age	42.98±13.53	44.23±17.25	37.18±18.60	38.27±18.32	40.52±11.33	42.27±9.62	0.207 (A) <0.0001 (C) * HCG ** (Z) TAG *** (Z)
NIP	100.00%	55.81%	22.95%	22.73%	63.64%	36.36%	TTG *** (Z) < 0.001 (A) * LIG > TAG * (Sc) LIG > HIVnG * (Sc)
LC	1.75±0.45	2.22±0.25	1.67±0.64	1.90±0.65	1.46±0.89	2.01±1.15	< 0.001 (A) * TAG > HCG * (Sc) GTA > HIVnG * (Sc) TAG > HIVTB-G * (Sc)
MC	0.44±0.21	0.54±0.25	0.70±0.37	0.54±0.25	0.40±0.31	0.45±0.22	< 0.001 (A) * TAG > HCG * (Sc) TAG > LIG* (Sc) TAG > TTG * (Sc) TAG > HIVTB-G* (Sc)
M/L	0.27±0.16	0.29±0.22	0.49±0.40	0.32±0.16	0.33±0.20	0.27±0.19	

HCG = healthy control group; LIG = Latent HIV negative Infected TB group; TAG = HIV negative active tuberculosis group; TTG = treated HIV negative group; HIVnG = HIV Naïve group; HIVTB-G = Co-infected HIV-tuberculosis group; NIP = Italian nationality patients; LC = lymphocytes; MC = monocytes; A = one way ANOVA test; C = multi-comparison chi square test; Z = Z-test; \* = significant test; \* \* = significant most frequent; \*\*\* = significant less frequent; Sc = Scheffé's test (it was performed with significant level less than 0.05); MC/LC = monocyte/lymphocyte ratio; lymphocyte and monocyte values were expressed in  $1 \times 10^3/\mu\text{l}$



**Figure 1.** The mean value of lymphocyte absolute blood cell count (LC) and monocyte absolute blood cell count (MC) for every group



**Figure 2.** Mean score of monocytes / lymphocytes for every group